Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: Am J Sports Med. 2020 May 26;48(8):1916–1928. doi: 10.1177/0363546520920591

Figure 5.

Figure 5.

Patient-reported outcomes. Changes in patient-reported outcome scores. Higher scores correspond to improved functional status. (A) Veterans RAND 12-Item Health Survey (VR-12) physical component summary (PCS), (B) VR-12 mental component summary (MCS), (C) International Knee Documentation Committee (IKDC) form, and Knee injury and Osteoarthritis Outcome Score (KOOS) subscales for (D) activities of daily living (ADL), (E) pain, (F) quality of life, (G) sport and recreation function, and (H) other symptoms. Values are shown as mean ± 90% CI. Patients in the human growth hormone (HGH) group are shown in black, and those in the placebo group are shown in gray. The thick black line indicates the treatment window for HGH or placebo, with the preoperative time point occurring before initiating HGH or placebo treatment. Differences were tested using mixed-effects models. Significance: †.05 ≤ P < .10 comparing HGH with placebo at a given time point; ‡P < .05 comparing HGH with placebo at a given time point; ^.05 ≤ P < .10 comparing the postoperative time point with the preoperative time point within the same treatment group; #P < .05 comparing the postoperative time point with the preoperative time point within the same treatment group.